AU2002211427A1 - Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors - Google Patents

Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Info

Publication number
AU2002211427A1
AU2002211427A1 AU2002211427A AU1142702A AU2002211427A1 AU 2002211427 A1 AU2002211427 A1 AU 2002211427A1 AU 2002211427 A AU2002211427 A AU 2002211427A AU 1142702 A AU1142702 A AU 1142702A AU 2002211427 A1 AU2002211427 A1 AU 2002211427A1
Authority
AU
Australia
Prior art keywords
inhibitors
effects
signal transduction
combined administration
farnesyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211427A
Inventor
George Q. Daley
Russell R. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of AU2002211427A1 publication Critical patent/AU2002211427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
AU2002211427A 2000-10-05 2001-10-04 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors Abandoned AU2002211427A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
US60/238,240 2000-10-05
US23881300P 2000-10-06 2000-10-06
US60/238,813 2000-10-06
PCT/US2001/031104 WO2002028409A2 (en) 2000-10-05 2001-10-04 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Publications (1)

Publication Number Publication Date
AU2002211427A1 true AU2002211427A1 (en) 2002-04-15

Family

ID=26931459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211427A Abandoned AU2002211427A1 (en) 2000-10-05 2001-10-04 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Country Status (3)

Country Link
US (2) US20020077301A1 (en)
AU (1) AU2002211427A1 (en)
WO (1) WO2002028409A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression
KR20080091866A (en) * 2001-05-16 2008-10-14 노파르티스 아게 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc Novel phenylamino-pyrimidines and uses thereof
US20050153975A1 (en) * 2002-02-22 2005-07-14 Heinrich Michael C. Use of 4-(4-Methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating seminomas
US20030211461A1 (en) * 2002-05-01 2003-11-13 Genoptix, Inc Optophoretic detection of durgs exhibiting inhibitory effect on Bcr-Abl positive tumor cells
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
JP2007510661A (en) * 2003-11-06 2007-04-26 シェーリング　コーポレイション Combination of farnesyltransferase inhibitor and antihormonal agent for the treatment of breast cancer
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2009511450A (en) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト Combination of nilotinib and farnesyltransferase inhibitor
WO2007110709A2 (en) * 2005-10-14 2007-10-04 Janssen Pharmaceutica, N.V. Formulations of tipifarnib for intravenous administration
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2743717A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20130302644A1 (en) * 2009-02-20 2013-11-14 Nucor Corporation Hot rolled thin cast strip product and method for making the same
RU2487961C2 (en) * 2011-10-24 2013-07-20 Открытое акционерное общество "Раменское приборостроительное конструкторское бюро" (ОАО "РПКБ") Method of quenching blanks from d16 aluminium alloy
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
WO1998057948A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
IL133448A0 (en) * 1997-06-17 2001-04-30 Schering Corp Benzo (5, 6) cyclohepta (1, 2-b) pyridine derivatives as farnesyl protein transferase inhibitors
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
US20010039952A1 (en) * 1998-11-10 2001-11-15 Walter A. Hacker, Ph. D Ultrasound enhanced chemotherapy
DE60004781T2 (en) * 1999-01-11 2004-07-08 Princeton University KINASE INHIBITORS WITH HIGH AFFINITY FOR TARGET DETECTION AND THEIR USE
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US20030022918A1 (en) * 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2003527437A (en) * 2000-03-20 2003-09-16 ファイザー・プロダクツ・インク Combination treatment with keratinocyte growth factor and epidermal growth factor inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20030229099A1 (en) * 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2002028409A2 (en) 2002-04-11
WO2002028409A3 (en) 2003-03-06
US20050020516A1 (en) 2005-01-27
US20020077301A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002211427A1 (en) Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
AU5772698A (en) Inhibitors of farnesyl protein transferase
AU2001243158A1 (en) Inhibitors of prenyl-protein transferase
AU2136697A (en) Inhibitors of farnesyl protein transferase
AU3880897A (en) Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
AU2002213485A1 (en) Inhibitors of protein kinases
IL133470A0 (en) Inhibitors of farnesyl protein transferase and pharmaceutical compositions containing same
AU4915796A (en) Inhibitors of prenyl transferases
EP1324985A4 (en) Inhibitors of prenyl-protein transferase
EP1027042A4 (en) Inhibitors of farnesyl protein transferase
AU2001238217A1 (en) Inhibitors of prenyl-protein transferase
AU2001247197A1 (en) Inhibitors of prenyl-protein transferase
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2477400A (en) Inhibitors of prenyl-protein transferase
AU7354900A (en) Inhibitors of prenyl-protein transferase
AU5164898A (en) Thioproline-containing inhibitors of farnesyl protein transferase
AU2001227757A1 (en) Inhibitors of prenyl-protein transferase
AU2001238424A1 (en) Inhibitors of prenyl-protein transferase
AU2274101A (en) Inhibitors of prenyl-protein transferase
AU2001230864A1 (en) Inhibitors of prenyl-protein transferase
HUP9904056A3 (en) Substituted benzocycloheptapyridine derivatives useful as inhibitor of farnesyl protein transferase and use thereof
AU6678398A (en) Inhibitors of isoprenyl transferase
AU2001229320A1 (en) Inhibitors of prenyl-protein transferase
AU2435199A (en) Farnesyl transferase inhibitors